{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:07:38Z","timestamp":1785409658341,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00228-010-0828-z","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T13:55:24Z","timestamp":1273672524000},"page":"661-669","source":"Crossref","is-referenced-by-count":7,"title":["Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara"],"prefix":"10.1007","volume":"66","author":[{"given":"Giacomo","family":"Chiabrando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Scanavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"key":"828_CR1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/bmj.310.6985.970","volume":"310","author":"A Ott","year":"1995","unstructured":"Ott A, Breteler M, van Harskamp F (1995) Prevalence of Alzheimer\u2019s disease and vascular dementia: association with education: the Rotterdam study. Br Med J 310:970\u2013973","journal-title":"Br Med J"},{"key":"828_CR2","unstructured":"Bird TD, Miller BL. Alzheimer\u2019s disease and other dementias. In: Kasper DL, Braunwald E, Fauci AS, et al (eds) Harrison's Internal Medicine. McGraw Hill, New York"},{"key":"828_CR3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1192\/bjp.163.4.467","volume":"163","author":"K Morgan","year":"1993","unstructured":"Morgan K, Lilley JM, Arie T (1993) Incidence of dementia in a representative British sample. Br J Psychiatry 163:467\u2013470","journal-title":"Br J Psychiatry"},{"key":"828_CR4","unstructured":"AIFA Ministero della Salute (2006) Alzheimer e inibitori delle colinesterasi: c\u2019\u00e8 qualcosa di nuovo? Boll d\u2019Inf Farm 13(1):19\u201325"},{"key":"828_CR5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJM200104123441501","volume":"344","author":"C Wolfson","year":"2001","unstructured":"Wolfson C, Wolfson DB, Asgharian M et al (2001) A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344:1111\u20131116","journal-title":"N Engl J Med"},{"key":"828_CR6","unstructured":"NHS National Institute for Health and Clinical Excellence (2007) NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer\u2019s disease. NHS, London"},{"key":"828_CR7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0149-2918(02)80004-2","volume":"24","author":"C Wolfson","year":"2002","unstructured":"Wolfson C, Oremus M, Shukla V et al (2002) Donepezil and rivastigmine in the treatment of Alzheimer\u2019s disease: a best evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 24:862\u2013886","journal-title":"Clin Ther"},{"key":"828_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/geront\/38.2.189","volume":"38","author":"C Beck","year":"1998","unstructured":"Beck C, Frank L, Chumbler NR (1998) Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist 38:189\u2013198","journal-title":"Gerontologist"},{"key":"828_CR9","first-page":"247","volume":"25","author":"BW Rovner","year":"1992","unstructured":"Rovner BW (1992) Behavioral and psychiatric disability in Alzheimer\u2019s disease. J Geriatr Psychiatry 25:247\u2013255","journal-title":"J Geriatr Psychiatry"},{"key":"828_CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1532-5415.1988.tb03427.x","volume":"36","author":"AE Merriam","year":"1988","unstructured":"Merriam AE, Aronson MK, Gasten P (1988) The psychiatric symptoms of Alzheimer\u2019s disease. J Am Geriatr Soc 36:7\u201312","journal-title":"J Am Geriatr Soc"},{"key":"828_CR11","first-page":"26","volume":"8","author":"DA Forbes","year":"2005","unstructured":"Forbes DA, Peacock S, Morgan D (2005) Non-pharmacological management of agitated behaviors associated with dementia. Geriatrics Aging 8:26\u201330","journal-title":"Geriatrics Aging"},{"key":"828_CR12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archinte.1995.00430030036004","volume":"155","author":"BF Yeager","year":"1995","unstructured":"Yeager BF, Farnett LE, Ruzicka SA (1995) Management of the behavior manifestations of dementia. Arch Intern Med 155:250\u2013260","journal-title":"Arch Intern Med"},{"key":"828_CR13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","volume":"293","author":"KM Sink","year":"2005","unstructured":"Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293:596\u2013608","journal-title":"JAMA"},{"key":"828_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmj.38125.465579.55","volume":"329","author":"PE Lee","year":"2004","unstructured":"Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA (2004) Atypical antipsychotic drugs in the treatment of behavior and psychological symptoms of dementia: systematic review. BMJ 329:75\u201379","journal-title":"BMJ"},{"key":"828_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00228-004-0868-3","volume":"61","author":"G Trifir\u00f2","year":"2005","unstructured":"Trifir\u00f2 G, Spina E, Brignoli O et al (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population based study during the years 1999\u20132002. Eur J Clin Pharmacol 61:47\u201353","journal-title":"Eur J Clin Pharmacol"},{"key":"828_CR16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1503\/cmaj.1040539","volume":"170","author":"E Wooltorton","year":"2004","unstructured":"Wooltorton E (2004) Olanzapine: increased incidence of cerebrovascular events in dementia trials. CMAJ 170:1395","journal-title":"CMAJ"},{"key":"828_CR17","first-page":"1269","volume":"167","author":"E Wooltorton","year":"2002","unstructured":"Wooltorton E (2002) Risperidone: increased rates of cerebrovascular events in dementia trials. CMAJ 167:1269","journal-title":"CMAJ"},{"key":"828_CR18","unstructured":"AIFA Ministero della Salute (2004) Importanti informazioni di sicurezza su risperidone e rischio di eventi cerebrovascolari nel trattamento delle psicosi e dei disturbi comportamentali in pazienti anziani affetti da demenza. Boll d\u2019Inf Farm 1:14"},{"key":"828_CR19","unstructured":"AIFA Ministero della Salute (2004) Importante informazione di sicurezza su olanzapina e rischio di mortalit\u00e0 e ictus nel trattamento delle psicosi e dei disturbi comportamentali in pazienti anziani affetti da demenza. Boll Inf Farm 1:15"},{"key":"828_CR20","unstructured":"Committee on Safety of Medicines (2004) Atypical antipsychotic drugs and stroke. http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/CON1004298"},{"key":"828_CR21","unstructured":"Ministero della Salute (2004) Chiarimenti riguardanti la prescrivibilit\u00e0 dei farmaci antipsicotici atipici da parte delle UVA. Farmacovigilanza News 7\u20138:4"},{"key":"828_CR22","unstructured":"FDA (2005) Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/UCM053171"},{"key":"828_CR23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","volume":"353","author":"PS Wang","year":"2005","unstructured":"Wang PS, Schneeweiss S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353:2335\u20132341","journal-title":"N Engl J Med"},{"key":"828_CR24","doi-asserted-by":"crossref","unstructured":"Trifir\u00f2 G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC (2006) All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 16:538\u2013544","DOI":"10.1002\/pds.1334"},{"key":"828_CR25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"12","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS et al (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med 12:1525\u20131538","journal-title":"N Engl J Med"},{"key":"828_CR26","doi-asserted-by":"crossref","unstructured":"Ballard C, Waite J, Birks J (2006) Atypical antipsychotics for aggression and psychosis in Alzheimer\u2019s disease. Cochrane Database Syst Rev 1:CD003476","DOI":"10.1002\/14651858.CD003476.pub2"},{"issue":"15","key":"828_CR27","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment. J Am Med Assoc 294(15):1934\u20131943","journal-title":"J Am Med Assoc"},{"key":"828_CR28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002280050275","volume":"52","author":"JU Rosholm","year":"1997","unstructured":"Rosholm JU, Gram LF, Isacsson G, Hallas J, Bergman U (1997) Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 52:205\u2013209","journal-title":"Eur J Clin Pharmacol"},{"key":"828_CR29","first-page":"191","volume":"90","author":"LA Daiello","year":"2007","unstructured":"Daiello LA (2007) Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I 90:191\u2013194","journal-title":"Med Health R I"},{"key":"828_CR30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/bmj.38782.575868.7C","volume":"332","author":"J Fossey","year":"2006","unstructured":"Fossey J, Ballard C, Juszczak E et al (2006) Effects of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomized trial. BMJ 332:756\u2013761","journal-title":"BMJ"},{"issue":"3","key":"828_CR31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"L Schneider","year":"2006","unstructured":"Schneider L, Dagerman K, Insel P (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14(3):191\u2013210","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"828_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ebmh.8.3.83","volume":"8","author":"BH Mulsant","year":"2005","unstructured":"Mulsant BH (2005) Review: pharmacotherapy provides minimal improvements in the neuropsychiatric symptoms of dementia. Evid Based Mental Health 8(3):83","journal-title":"Evid Based Mental Health"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0828-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0828-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0828-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:52:07Z","timestamp":1558702327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0828-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0828-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]}}}